文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经鼻高流量氧疗联合无创通气作为急性呼吸衰竭初始氧疗的疗效:Meta分析

Efficacy of HFNC + NIV as initial oxygen therapy in acute respiratory failure: Meta-analysis.
PubMed 文献 · Am J Emerg Med · 2025-09-19
一句话结论在急性呼吸衰竭成人中,初始NIV+HFNC联合治疗与单用NIV或HFNC相比,插管率和死亡率均无显著差异。

该Meta分析纳入6项RCT、共764例急性呼吸衰竭成人,比较初始NIV+HFNC联合治疗与NIV或HFNC单药治疗对插管率和死亡率的影响。结果显示联合治疗未显著降低插管率(OR 1.08,95%CI 0.79-1.49,P=0.62,I²=23%)或死亡率(OR 1.41,95%CI 0.60-3.34,P=0.43,I²=62%)。按对照干预(单用NIV或单用HFNC)和试验设计(单中心 vs 多中心)的亚组分析也均无统计学显著差异。作者指出最大型研究呈现相反趋势,可能归因于NIV期间肺保护性通气策略的差异,未来需标准化方案和更大样本的高质量RCT。

要点

  • 6项RCT、764例急性呼吸衰竭成人中,初始NIV+HFNC联合治疗与单药治疗相比,插管率无显著差异(OR 1.08,95%CI 0.79-1.49)。
  • 死亡率同样无显著差异(OR 1.41,95%CI 0.60-3.34),95%CI宽且异质性I²=62%。
  • 按对照为单用NIV或单用HFNC的亚组分析、按单中心 vs 多中心的亚组分析均无统计学显著差异。
  • 最大型研究间呈现相反趋势,作者认为可能源于NIV期间肺保护性通气策略的差异。
  • 作者建议未来RCT优先标准化方案、明确肺保护性NIV设置、扩大样本量,并关注可能从联合治疗获益的特定急性呼吸衰竭表型。

适用人群与场景

  • 成人急性呼吸衰竭患者,纳入6项RCT共764例参与者。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入6项RCT,共764例急性呼吸衰竭成人,检索PubMed、Embase、Cochrane Library和Web of Science(建库至2025年5月31日)。
  • 干预与对照:初始NIV+HFNC联合治疗 vs NIV或HFNC单药治疗。
  • 主要终点插管率:联合治疗与单药治疗无显著差异(OR 1.08,95%CI 0.79-1.49;P=0.62;I²=23%)。
  • 次要终点死亡率:联合治疗与单药治疗无显著差异(OR 1.41,95%CI 0.60-3.34;P=0.43;I²=62%)。
  • 亚组分析:按对照干预(单用NIV或单用HFNC)和试验设计(单中心 vs 多中心)分层,均无统计学显著差异。
  • 最大型研究呈现相反趋势,作者认为可能归因于NIV期间肺保护性通气策略的差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入6项RCT,采用Cochrane RoB 2评估偏倚风险。
  • 异质性:插管率分析I²=23%,死亡率分析I²=62%。
  • 局限:作者指出未来需高质量RCT优先标准化方案、明确肺保护性NIV设置、扩大样本量,并关注特定急性呼吸衰竭表型。

对床旁实践的改变

  • 对于成人急性呼吸衰竭,初始NIV+HFNC联合治疗与单用NIV或HFNC相比,未能显著降低插管率或死亡率,不支持将联合治疗作为常规初始策略以改善这两项结局。
  • 最大型研究间趋势相反且可能与NIV期间肺保护性通气策略差异有关,提示临床实施NIV时应关注肺保护性通气设置,但作者未据此给出具体推荐。
  • 作者认为未来需标准化方案和更大样本RCT,并关注可能从联合治疗获益的特定急性呼吸衰竭表型。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Combining non-invasive ventilation (NIV) and high-flow nasal cannula (HFNC) may offer complementary benefits in acute respiratory failure (ARF). Prior meta-analyses compared monotherapies or post-extubation combination therapy, but none specifically evaluated NIV + HFNC as the initial strategy to prevent intubation or mortality.

OBJECTIVES: To compare the efficacy of initial NIV + HFNC versus NIV or HFNC monotherapy for preventing intubation and mortality in adults with ARF.

METHODS: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science (inception to May 31, 2025) for relevant RCTs. Primary outcome was intubation rate; secondary outcome was mortality. Statistical data analysis was performed using RevMan software. Risk of bias was assessed (Cochrane RoB 2).

RESULTS: Six RCTs (N = 764 participants) were included. Compared with monotherapy, combined NIV + HFNC did not significantly affect intubation rates (OR 1.08, 95 % CI 0.79-1.49; P = 0.62; I2 = 23 %) or mortality (OR 1.41, 95 % CI 0.60-3.34; P = 0.43; I2 = 62 %). Subgroup analyses by control intervention (NIV alone or HFNC alone) and trial design (single-center vs. multi-center) also showed no statistically significant differences. Notably, the largest studies exhibited contrasting trends, potentially attributable to variations in lung-protective ventilation strategies during NIV.

CONCLUSIONS: This meta-analysis found no significant benefit of initial NIV + HFNC over monotherapy in reducing intubation or mortality in ARF. Future high-quality RCTs should prioritize standardized protocols, explicit lung-protective NIV settings, and larger sample sizes, with particular emphasis on specific ARF phenotypes that may derive maximal benefit from combined therapy.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Wang W, Zhang P, Xu T, et al. Efficacy of HFNC + NIV as initial oxygen therapy in acute respiratory failure: Meta-analysis. Am J Emerg Med. 2025. PMID: 41344140. doi:10.1016/j.ajem.2025.09.036

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。